葡萄糖的情况
Sanjay Kalra1, Navneet Agrawal2, Nitin Kapoor3
1Department of Endocrinology, Bharti Hospital, Karnal, India; University Center for Research & Development, Chandigarh University, India.
JPMA. The Journal of the Pakistan Medical Association
|December 11, 2025
概括
我们介绍了糖尿病患者疼痛的术语 - - 葡萄糖,它涵盖了感官和情感体验. 这种情况是由各种因素引起的,包括微血管,代谢和与药物相关的原因,并且可以通过特定的疗法来管理.
科学领域:
- 内分泌学 在内分泌学.
- 神经学 神经学
- 疼痛医学 医学 疼痛医学
背景情况:
- 疼痛是糖尿病患者的常见并发症.
- 糖尿病疼痛可以既有害又有保护作用,影响生活质量.
- 现有的术语并不完全捕捉到糖尿病疼痛的复杂性.
研究的目的:
- 为糖尿病患者所经历的疼痛提出并定义一个新的术语"葡萄糖症".
- 阐明基于葡萄糖的多种机制.
- 概述治疗策略来管理糖尿病患者的疼痛.
主要方法:
- 文献综述和现有关于糖尿病疼痛机制研究的综合研究.
- 对"葡萄糖"一词的概念框架的开发.
- 葡萄糖的潜在原因的分类.
主要成果:
- 葡萄糖症被定义为与糖尿病相关的不愉快的感觉和情绪体验.
- 确定的潜在原因包括微血管,肌肉骨,新陈代谢,情绪相关和阳性因素.
- 介绍了糖尿病疼痛机制的全面概述.
结论:
- 术语"葡萄糖症"为了解与糖尿病相关的疼痛提供了一个统一的概念.
- 认识到葡萄糖的多因素性质对于有效管理至关重要.
- 有治疗方法可以缓解糖尿病患者的疼痛感觉.
相关概念视频
Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
Hypoglycemia and Glucagon
772
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
772
Glucagon-like Receptor Agonists
818
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
818
Dipeptidyl Peptidase 4 Inhibitors
557
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
557
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
505
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
505
Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562


